Market Overview:
On the basis of type, the market is segmented into AEM-2802, AEM-2814, alirocumab (Praluent), evinacumab (Repatha), and others. On the basis of application, the market is segmented into clinic setting, hospital setting,, and others. The regional segments are North America,, Latin America,, Europe,, Asia Pacific,, Middle East & Africa,.
Product Definition:
This treatment is important because it can help prevent heart disease and other health problems in people with this condition.
AEM-2802:
AEM-2814:
AEM-2814 is an investigational drug developed by Atherosclerosis Therapeutics, Inc. The disease has a prevalence rate of 1 in 40,000 to 50,000 people worldwide according to research studies.
Application Insights:
The other applications include research studies and home care management. Clinic-based therapy is expected to dominate the overall market over the forecast period owing to increasing awareness about HFC among patients as well as healthcare professionals, which has resulted in increased demand for these therapies.
The hospital based segment is also expected to witness significant growth during the same period owing to rising prevalence of cardiovascular diseases (CVDs) globally coupled with an increase in patient admissions for new diagnostic procedures related with HFC such as genetic testing or lifestyle modification programs that are aimed at reducing cholesterol levels. In addition, a rise in number of hospitals offering specialized clinics catering specifically towards HFC would also boost industry growth over the forecast period.
Regional Analysis:
North America dominated the global market in 2017 owing to favorable healthcare infrastructure, high awareness levels coupled with relatively higher healthcare expenditure. Moreover, the availability of effective treatment options is also expected to drive regional growth over the forecast period.
Asia Pacific is expected to witness lucrative CAGR during the forecast period due to rising disposable income and improving economic conditions in emerging countries such as India and China. In addition, there are several ongoing clinical trials for evaluating new therapies for treating this condition which will further fuel regional demand during the forecast period (Ref: ClinicalTrials.gov).
Growth Factors:
- Growing awareness about the benefits of early diagnosis and treatment for Homozygous Familial Hypercholesterolemia (HoFH) is expected to drive market growth.
- The increasing prevalence of obesity and other risk factors for HoFH is also anticipated to fuel market growth over the forecast period.
- The development of novel therapies and treatments is expected to provide a boost to the Homozygous Familial Hypercholesterolemia Treatment market growth over the forecast period.
- Rising demand from emerging markets is projected to create new opportunities for players in the Homozygous Familial Hypercholesterolemia Treatment market in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Homozygous Familial Hypercholesterolemia Treatment Market Research Report
By Type
AEM-2802, AEM-2814, Alirocumab, Evinacumab, Others
By Application
Clinic, Hospital, Others
By Companies
CymaBay Therapeutics Inc, Daewoong Co Ltd, Gemphire Therapeutics Inc, LipimetiX Development Inc, Regeneron Pharmaceuticals Inc, RegenxBio Inc, The Medicines Company
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Homozygous Familial Hypercholesterolemia Treatment Market Report Segments:
The global Homozygous Familial Hypercholesterolemia Treatment market is segmented on the basis of:
Types
AEM-2802, AEM-2814, Alirocumab, Evinacumab, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- CymaBay Therapeutics Inc
- Daewoong Co Ltd
- Gemphire Therapeutics Inc
- LipimetiX Development Inc
- Regeneron Pharmaceuticals Inc
- RegenxBio Inc
- The Medicines Company
Highlights of The Homozygous Familial Hypercholesterolemia Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- AEM-2802
- AEM-2814
- Alirocumab
- Evinacumab
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Homozygous Familial Hypercholesterolemia Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no cure for homozygous familial hypercholesterolemia, but there are treatments that can help manage the disease. Treatment options may include lifestyle changes, medications, and surgery. Some people with homozygous familial hypercholesterolemia may need to take cholesterol-lowering medications all their lives to maintain a healthy level of cholesterol in their blood. Surgery may be necessary if other treatments fail to control the levels of cholesterol in the blood or if symptoms such as heart disease or stroke occur due to high levels of cholesterol.
Some of the major companies in the homozygous familial hypercholesterolemia treatment market are CymaBay Therapeutics Inc, Daewoong Co Ltd, Gemphire Therapeutics Inc, LipimetiX Development Inc, Regeneron Pharmaceuticals Inc, RegenxBio Inc, The Medicines Company.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Homozygous Familial Hypercholesterolemia Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Homozygous Familial Hypercholesterolemia Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Homozygous Familial Hypercholesterolemia Treatment Market - Supply Chain
4.5. Global Homozygous Familial Hypercholesterolemia Treatment Market Forecast
4.5.1. Homozygous Familial Hypercholesterolemia Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Homozygous Familial Hypercholesterolemia Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Homozygous Familial Hypercholesterolemia Treatment Market Absolute $ Opportunity
5. Global Homozygous Familial Hypercholesterolemia Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Homozygous Familial Hypercholesterolemia Treatment Market Size and Volume Forecast by Type
5.3.1. AEM-2802
5.3.2. AEM-2814
5.3.3. Alirocumab
5.3.4. Evinacumab
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Homozygous Familial Hypercholesterolemia Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Homozygous Familial Hypercholesterolemia Treatment Market Size and Volume Forecast by Application
6.3.1. Clinic
6.3.2. Hospital
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Homozygous Familial Hypercholesterolemia Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Homozygous Familial Hypercholesterolemia Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Homozygous Familial Hypercholesterolemia Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Homozygous Familial Hypercholesterolemia Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Homozygous Familial Hypercholesterolemia Treatment Demand Share Forecast, 2019-2026
9. North America Homozygous Familial Hypercholesterolemia Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Homozygous Familial Hypercholesterolemia Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Homozygous Familial Hypercholesterolemia Treatment Market Size and Volume Forecast by Application
9.4.1. Clinic
9.4.2. Hospital
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Homozygous Familial Hypercholesterolemia Treatment Market Size and Volume Forecast by Type
9.7.1. AEM-2802
9.7.2. AEM-2814
9.7.3. Alirocumab
9.7.4. Evinacumab
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Homozygous Familial Hypercholesterolemia Treatment Demand Share Forecast, 2019-2026
10. Latin America Homozygous Familial Hypercholesterolemia Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Homozygous Familial Hypercholesterolemia Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Homozygous Familial Hypercholesterolemia Treatment Market Size and Volume Forecast by Application
10.4.1. Clinic
10.4.2. Hospital
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Homozygous Familial Hypercholesterolemia Treatment Market Size and Volume Forecast by Type
10.7.1. AEM-2802
10.7.2. AEM-2814
10.7.3. Alirocumab
10.7.4. Evinacumab
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Homozygous Familial Hypercholesterolemia Treatment Demand Share Forecast, 2019-2026
11. Europe Homozygous Familial Hypercholesterolemia Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Homozygous Familial Hypercholesterolemia Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Homozygous Familial Hypercholesterolemia Treatment Market Size and Volume Forecast by Application
11.4.1. Clinic
11.4.2. Hospital
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Homozygous Familial Hypercholesterolemia Treatment Market Size and Volume Forecast by Type
11.7.1. AEM-2802
11.7.2. AEM-2814
11.7.3. Alirocumab
11.7.4. Evinacumab
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Homozygous Familial Hypercholesterolemia Treatment Demand Share, 2019-2026
12. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Market Size and Volume Forecast by Application
12.4.1. Clinic
12.4.2. Hospital
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Market Size and Volume Forecast by Type
12.7.1. AEM-2802
12.7.2. AEM-2814
12.7.3. Alirocumab
12.7.4. Evinacumab
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Demand Share, 2019-2026
13. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Market Size and Volume Forecast by Application
13.4.1. Clinic
13.4.2. Hospital
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Market Size and Volume Forecast by Type
13.7.1. AEM-2802
13.7.2. AEM-2814
13.7.3. Alirocumab
13.7.4. Evinacumab
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Homozygous Familial Hypercholesterolemia Treatment Market: Market Share Analysis
14.2. Homozygous Familial Hypercholesterolemia Treatment Distributors and Customers
14.3. Homozygous Familial Hypercholesterolemia Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. CymaBay Therapeutics Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Daewoong Co Ltd
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Gemphire Therapeutics Inc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. LipimetiX Development Inc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Regeneron Pharmaceuticals Inc
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. RegenxBio Inc
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. The Medicines Company
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
